share_log

Gilead Sciences | 10-Q: Q3 2024 Earnings Report

Gilead Sciences | 10-Q: Q3 2024 Earnings Report

吉利德科學 | 10-Q：2024財年三季報
美股SEC公告 ·  11/12 22:32

Moomoo AI 已提取核心訊息

Gilead Sciences reported Q3 2024 total revenues of $7.5 billion, up 7% year-over-year, driven by higher HIV product sales. Net income attributable to Gilead decreased 43% to $1.3 billion, primarily due to a $1.8 billion IPR&D impairment charge related to Trodelvy for NSCLC. Diluted EPS fell 42% to $1.00.HIV product sales grew 9% to $5.1 billion, led by Biktarvy's 13% increase. Oncology sales rose 6% to $816 million, with Trodelvy up 17%. Veklury (remdesivir) sales increased 9% to $692 million amid higher COVID-19 hospitalizations. R&D expenses decreased 4% to $1.4 billion due to the wind-down of certain clinical studies.Gilead maintained its full-year 2024 guidance. The company ended Q3 with $5.0 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, after completing the $3.9 billion acquisition of CymaBay Therapeutics in March. Gilead continues to invest in its pipeline while returning capital to shareholders through dividends and share repurchases.
Gilead Sciences reported Q3 2024 total revenues of $7.5 billion, up 7% year-over-year, driven by higher HIV product sales. Net income attributable to Gilead decreased 43% to $1.3 billion, primarily due to a $1.8 billion IPR&D impairment charge related to Trodelvy for NSCLC. Diluted EPS fell 42% to $1.00.HIV product sales grew 9% to $5.1 billion, led by Biktarvy's 13% increase. Oncology sales rose 6% to $816 million, with Trodelvy up 17%. Veklury (remdesivir) sales increased 9% to $692 million amid higher COVID-19 hospitalizations. R&D expenses decreased 4% to $1.4 billion due to the wind-down of certain clinical studies.Gilead maintained its full-year 2024 guidance. The company ended Q3 with $5.0 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, after completing the $3.9 billion acquisition of CymaBay Therapeutics in March. Gilead continues to invest in its pipeline while returning capital to shareholders through dividends and share repurchases.
吉利德科學報告了2024年第三季度總收入爲75億元，同比增長7%，主要受益於HIV產品銷售增長。歸屬於吉利德的凈利潤減少了43%，降至13億元，主要由於與Trodelvy相關的18億元知識產權與研發減值費用。攤薄後每股收益下降42%，降至1.00美元。HIV產品銷售增長9%，達到51億元，主要由Biktarvy的13%增長推動。腫瘤學銷售增長6%，達到81600萬元，Trodelvy增長17%。Veklury（瑞德西韋）銷售增長9%，達到69200萬元，因COVID-19住院人數增加。研發費用減少4%，降至14億元，因部分臨牀研究的結束。吉利德維持其2024年的全年指導。公司在第三季度末手握現金和現金等價物50億元，較2023年末的84億元下降，此前完成了對CymaBay Therapeutics 39億元的收購。吉利德繼續投資於其產品線，同時通過分紅派息和分享回購向股東返還資本。
吉利德科學報告了2024年第三季度總收入爲75億元，同比增長7%，主要受益於HIV產品銷售增長。歸屬於吉利德的凈利潤減少了43%，降至13億元，主要由於與Trodelvy相關的18億元知識產權與研發減值費用。攤薄後每股收益下降42%，降至1.00美元。HIV產品銷售增長9%，達到51億元，主要由Biktarvy的13%增長推動。腫瘤學銷售增長6%，達到81600萬元，Trodelvy增長17%。Veklury（瑞德西韋）銷售增長9%，達到69200萬元，因COVID-19住院人數增加。研發費用減少4%，降至14億元，因部分臨牀研究的結束。吉利德維持其2024年的全年指導。公司在第三季度末手握現金和現金等價物50億元，較2023年末的84億元下降，此前完成了對CymaBay Therapeutics 39億元的收購。吉利德繼續投資於其產品線，同時通過分紅派息和分享回購向股東返還資本。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間